Sorted By Test Name - Mayo Medical Laboratories

MONOS
9081
IBDP
81443
Salt Lake City, UT 84108
Infectious Mononucleosis, Rapid Test, Serum
Clinical Information: Infectious mononucleosis (IM) is a viral illness that involves
reticuloendothelial tissue and is generally limited to children and young adults. IM is most commonly
caused by Epstein-Barr virus (EBV). The disease is characterized by fever, sore throat, lymphadenopathy,
headache, and fatigue, and on a symptomatic basis may be confused with other diseases. Detectable levels
of unique heterophile antibodies are produced in patients with IM.
Useful For: Rapid confirmation of a diagnosis of infectious mononucleosis
Interpretation: Detectable levels of the infectious mononucleosis (IM) heterophile antibody can
usually be expected to occur between the sixth and tenth day following the onset of symptoms. The level
usually increases through the second or third week of illness and, thereafter, can be expected to persist,
gradually declining over a 12-month period.
Reference Values:
Negative (reported as positive or negative)
Clinical References: 1. Davidsohn I, Walker PH: The nature of heterophilic antibodies in infectious
mononucleosis. Am J Clin Pathol 1935;5:445-465 2. Peter J, Ray CG: Infectious mononucleosis. Pediatr
Rev 1998;19(8):276-279
Inflammatory Bowel Disease Serology Panel, Serum
Clinical Information: The term "inflammatory bowel disease" (IBD) is often used to refer to 2
diseases, ulcerative colitis (UC) and Crohn's disease (CD), that produce inflammation of the large or small
intestines. The diagnosis of these 2 diseases is based on clinical features, the results of barium X-rays,
colonoscopy, mucosal biopsy histology, and in some cases operative findings and resected bowel
pathology and histology. Recently, patients with IBD have been shown to have antibodies in serum that
help to distinguish between CD and UC.(1) Patients with UC often have measurable neutrophil specific
antibodies (NSA), which react with as yet uncharacterized target antigens in human neutrophils; whereas,
patients with CD often have measurable antibodies of the IgA and/or IgG isotypes, which react with cell
wall mannan of Saccharomyces cerevisiae strain Su 1.
Useful For: As an adjunct in the diagnosis of ulcerative colitis and Crohns disease in patients suspected
of having inflammatory bowel disease
Interpretation: The finding of neutrophil specific antibodies (NSA) with normal levels of IgA and IgG
anti-Saccharomyces cerevisiae antibodies (ASCA) is consistent with the diagnosis of ulcerative colitis
(UC); the finding of negative NSA with elevated IgA and IgG ASCA is consistent with Crohn's disease
(CD). NSA are detectable in approximately 50% of patients with UC, and elevated levels of either IgA or
IgG ASCA occur in approximately 55% of patients with CD. Approximately 40% of patients with CD
have elevated levels of both IgA and IgG ASCA. Employed together, the tests for NSA and ASCA have
the following positive predictive values (PV) for UC and CD, respectively: NSA positive with normal
levels of IgA and IgG ASCA, PV of 91%; NSA negative with elevated levels if IgA and IgG ASCA, PV
of 90%.(2)
Reference Values:
Saccharomyces cerevisiae ANTIBODY, IgA
Negative: 0.0-20.0 U
Equivocal: 20.1-24.9 U
Weakly positive: 25.0-34.9 U
Positive: > or =35.0 U
Saccharomyces cerevisiae ANTIBODY, IgG
Negative: 0.0-20.0 U
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1018